Medicine and Dentistry
Liver Cirrhosis
100%
Liver Transplantation
62%
Liver Graft
54%
End Stage Liver Disease
30%
Hepatic Encephalopathy
30%
Hepatitis C Virus
29%
Infection
26%
Allograft
24%
Acute on Chronic Liver Failure
24%
Fibrosis
24%
Antibody Mediated Rejection
23%
Transplantation
20%
Hepatitis C
18%
Graft Survival
17%
Antibodies
17%
Liver Disease
16%
Model For End Stage Liver Disease Score
16%
HLA Antibody
16%
Acute Kidney Injury
16%
Ascites
16%
Alloantibody
14%
Recurrent Disease
12%
Spontaneous Bacterial Peritonitis
11%
Hazard Ratio
10%
Frailty
10%
Graft Failure
10%
Decompensated Liver Cirrhosis
10%
Model for End-Stage Liver Disease
9%
Creatinine
9%
Hepatology
9%
Human Leukocyte Antigen
8%
Outpatient
7%
Complement Component C4d
7%
Sensitization
7%
Odds Ratio
7%
Paracentesis
6%
Immunosuppressive Treatment
6%
Intestine Transplantation
6%
Meta-Analysis
6%
Systematic Review
6%
Kidney Function
5%
Logistic Regression Analysis
5%
Chronic Kidney Disease
5%
Bacterial Infection
5%
Biopsy
5%
Hospital Infection
5%
Body Mass Index
5%
Chronic Hepatitis C
5%
Kidney Transplantation
5%
Keyphrases
Liver Transplantation
66%
Cirrhosis
61%
Liver Transplant Recipients
21%
MELD Score
21%
Acute-on-chronic Liver Failure
19%
End-stage Liver Disease
19%
Hepatitis C
17%
Hepatitis C Virus
16%
Hospitalized Patients
15%
North America
13%
HLA Antibodies
12%
Acute Kidney Injury
12%
Donor-specific Antibodies
12%
Spontaneous Bacterial Peritonitis
10%
Organ Failure
10%
Advanced Fibrosis
10%
Chronic Antibody-mediated Rejection
10%
Graft Survival
9%
Acute Rejection
9%
Graft Loss
9%
Hazard Ratio
9%
Liver
8%
Ascites
8%
Liver Disease
8%
Hepatic Encephalopathy
8%
Patient Survival
8%
Extrahepatic Organs
8%
Mean Fluorescence Intensity
8%
Transplantation
7%
In-hospital Mortality
7%
High Risk
7%
Hepatology
7%
NACSELD
6%
Orthotopic Liver Transplantation
6%
Antibody-mediated Rejection
6%
Transplant Survival
6%
Disease Experience
6%
Recipient Characteristics
6%
Paracentesis
6%
Alcoholic Liver Disease
6%
Confidence Interval
6%
Chronic Hepatitis C
6%
United States
6%
Second Infection
5%
30-day Survival
5%
Decompensated Cirrhosis
5%
Recurrent Disease
5%
Multivariable
5%
Hepatitis C Virus Infection
5%
Body Mass Index
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cirrhosis
52%
Hepatitis C
38%
Hepatitis C Virus
23%
Fibrosis
23%
Acute on Chronic Liver Failure
16%
End Stage Liver Disease
15%
Hepatic Encephalopathy
15%
Ribavirin
13%
Bacterial Peritonitis
12%
Recurrent Disease
8%
Sofosbuvir
8%
Simeprevir
8%
Interferon
8%
Proteinase Inhibitor
7%
Infection
6%
Hepatitis C Antibody
6%
Velpatasvir
6%
Frailty
6%
Boceprevir
6%
Telaprevir
6%
Mixed Infection
6%
Antivirus Agent
6%
Clinical Trial
6%
Decompensated Liver Cirrhosis
6%
Creatinine
5%
Cohort Study
5%
Antiviral Therapy
5%
Ascites
5%
Prevalence
5%
